Clinical Trial Update: Usability, Immediate, and 30 Day Effect of External Neuromodulation With iTEAR100 Generation 2 in Dry Eye Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update on external neuromodulation device iTEAR100 Generation 2 for dry eye, evaluating usability and short-term effects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye

Drugs mentioned

• iTEAR100 Generation 2

Snippet

Sponsor: Olympic Ophthalmics, Inc. | Conditions: Dry Eye | Phase 4 | Status: UNKNOWN